Geron Corporation Projects 2026 RYTELO Revenue Between $220M and $240M
Geron Corporation (GERN) has provided a long-term revenue outlook for its product, RYTELO, projecting net sales between $220 million and $240 million for the year 2026. The company is focused on scaling its commercial presence in the myelodysplastic syndromes (MDS) market, citing consistent demand growth within the United States. As part of its international expansion strategy, Geron plans to initiate the launch of RYTELO in Germany by the end of this year. Management expressed confidence in the product's growth trajectory and reiterated their strategic goal to establish the company as a leader in the hematology sector.
Tickers: $GERN
Topics: commercial growth earnings call hematology RYTELO demand
Read the full article at Seeking Alpha
Part of the story American Well Corporation Projects Q4 2026 Revenue Between $48M and $50M (3 articles)